

Stephen Phua, MD



Current Engagements:

Dr Phua spent more than 30 years in the pharmaceutical and healthcare industry. As a medical doctor with a wide range of successful senior positions in several multinational companies, Dr. Phua is retained as a staff consultant of Pavilion Capital, a fully owned subsidiary of Temasek and spend the last 7 years with the private equity fund doing healthcare investment in Asia.

He is the Chairman of Menarini Biomarkers, a leader in single cell Omics.

Past Engagements:

Dr Phua was an adviser Bionova, a Melbourne-based Biotech company and Kalbe Farma and ChoongWae, one of the largest pharmaceutical companies in Indonesia and Korea respectively. He was the Chairman of the scientific advisory board of Genexine, a Kosdaq listed biotech company.

He was on the board of Zuellig Pharmaceutical, a leading distributor of biopharma products and devices in Asia.

Through his extensive career in the health and life science industry, he has had senior executive appointments spanning across a wide range of the healthcare sectors – biopharmaceuticals, devices, diagnostic and hospital services in Asia Pacific.

In the biopharmaceutical sector, Dr. Phua started with Wellcome, which was subsequently acquired by GSK, initially as the regional medical director in SE Asia driving the clinical development of the new portfolio of antiviral products including the first HIV drug. He subsequently was involved in the commercialisation of these products as the General Manager of Wellcome Singapore.

He started the oncology franchise of Rhone Poulenc which was subsequently acquired by Sanofi Aventis in Asia Pacific having responsibility for the clinical as well as commercial development of Taxotere, G-CSF and Camptothecin.

He was the Head of Asia Pacific for Covance, a leading CRO in Asia Pacific and was involved in developing the early and late clinical development competencies and infrastructure among many academic centres, public and private hospitals in Asia including China.

In the diagnostic sector, Dr. Phua was the Chief Executive Officer of Agenix Limited, listed on the Australian Stock Exchange. During his tenure, he supervised the completion of the phase II study for Thromboview, a diagnostic scan for pulmonary embolism and design the phase III study in the USA.

Dr. Phua was also involved in the health informatics and consulting space as President of Asia Pacific of IMS Health. IMS was the world's leading provider of information solutions to the pharmaceutical and healthcare industries and is now merged with Quintiles as the new entity IQVIA.

He was also the Group General Manager of Parkway Group Hospitals, the largest private hospital group in Asia.

Dr. Phua, who received his medical degree from the University of Singapore, has his postgraduate degree as a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physician, UK. He graduated Summa Cum Laude Masters of Science in Human Nutrition from the University of Bridgeport USA. He did his executive training at INSEAD, Fountainebleau.